The Importance of Fecal and Plasma CEA, COX-2, MMP-7, and TIMP-1 in the Diagnosis of Colorectal Cancer
The Importance of Fecal and Plasma CEA, COX-2, MMP-7, and TIMP-1 in the Diagnosis of Colorectal Cancer
Purpose: Colorectal cancer (CRC) is one of the most common and death related cancers in the world. Therefore, the early diagnosis of CRCremains with a great importance to prevent its further progression and increase survival rates. Colonoscopy and pathological examinationswhich are invasive and painful procedures, are needed to make a definitive diagnosis of CRC. The carcinoembryonic antigen (CEA) is particularlyused for postoperative follow-up of CRC patients. The imbalance between matrix metalloproteinases (MMPs) and their tissue inhibitors ofmetalloproteinases (TIMPs) leads to degradation of extracellular matrix which is the most important step in invasion and metastasis. It was alsoobserved that cyclooxygenase-2 (COX-2) has crucial roles in the development and progression of colorectal cancer. The purpose of our studyis to detect fecal and plasma MMP-7, COX-2, TIMP-1, and CEA protein levels in patients with colorectal cancer, colorectal polyps, and healthyindividuals, and assess their association with each other and with clinicopathological variables. We also aimed to evaluate plasma and fecalMMP-7, COX-2, TIMP-1, and CEA protein levels as potential diagnostic markers in colorectal carcinoma.Methods: Plasma and fecal samples were taken from patients with fifteen colorectal cancers, twenty-six colorectal polyps, and thirty-threehealthy volunteers. Protein extraction was carried out from fecal samples. Plasma and fecal MMP-7, TIMP-1, and COX-2 protein levels weredetermined by ELISA whereas plasma and fecal CEA protein levels were detected with CEIA.Results: Plasma and fecal CEA levels were significantly higher in CRC than the control. In addition, plasma TIMP-1 and plasma CEA levels weresignificantly elevated in cancer according to polyp group. We also detected decreased plasma MMP-7 levels in polyps compared to controlgroup. Positive correlations were observed among plasma COX-2 and TIMP-1 levels (r=0.571), fecal COX-2 and CEA levels (r=0.764) in CRC.However, no association was found between biochemical parameters and clinicopathological variables. ROC analysis for discriminating CRCfrom healthy controls showed that area under curves (AUC) for fecal and plasma CEA levels were 0.763 and 0.692, respectively. Plasma CEA(AUC=0.735), plasma TIMP-1 (AUC=0.706), and their combination (AUC=0.760) exhibited significant diagnostic performances to differentiateCRC from polyp. In discrimination colorectal polyps from healthy tissues, MMP-7 showed the highest AUC value (0.667).Conclusion: Here we suggested that plasma and fecal CEA protein levels may be potential predictive noninvasive markers for diagnosis ofcolorectal adenocarcinoma. In addition, plasma CEA and TIMP-1 are also valuable biomarker candidates in differentiating colorectal cancerfrom colorectal polyps.
___
- Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on
the status of cancer, 1973–1997, with a special section on colorectal
cancer. Cancer 2000;88:2398–2424.
- Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on
the status of cancer, 1973–1999, featuring implications of age and
aging on U. S. cancer burden. Cancer 2002;94:2766–2792.
- Hundt S, Haug U, Brenner H. Blood markers for early detection of
colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers
Prev 2007;16:1935–1953. [CrossRef]
- Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin
expression with recurrence and poor prognosis in human esophageal
squamous cell carcinoma. Cancer Res 1999;59:3313–3316.
- Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T, Kuwano H.
Clinical significance of mucin phenotype, beta-catenin and matrix
metalloproteinase 7 in early undifferentiated gastric carcinoma. Br J
Surg 2005;92:454–462. [CrossRef]
- Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution
of matrilysin (MMP-7) to the metastatic pathway of human colorectal
cancers. Gut 1999;45:252–258.
- Yamamoto H, Itoh F, Iku S, et al. Expression of matrix metalloproteinases
and tissue inhibitors of metalloproteinases in human pancreatic
adenocarcinomas: clinicopathologic and prognostic significance of
matrilysin expression. J Clin Oncol 2001;19:1118–1127. [CrossRef]
- Takeuchi N, Ichikawa Y, Ishikawa T, et al. Matrilysin gene expression
in sporadic and familial colorectal adenomas. Mol Carcinog
1997;19:225–229.
- Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors
of metalloproteinases in colonic adenomas-adenocarcinomas. Dis
Colon Rectum 1996;39:1255–1264.
- Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome
Biol 2004;5(9):241. [CrossRef]
- Dubois MA, Sabatier P, Durand B, Calavas D, Ducrot C, ChalvetMonfray K. Multiplicative genetic effects in scrapie disease
susceptibility. C R Biol 2002;325:565–570.
- Nastase A, Paslaru L, Niculescu AM, et al. Prognostic and predictive
potential molecular biomarkers in colon cancer. Chirurgia (Bucur)
2011;106:177–185.
- Keles D, Arslan B, Terzi C, et al. Expression and activity levels of matrix
metalloproteinase-7 and in situ localization of caseinolytic activity in
colorectal cancer. Clin Biochem 2014;47:1265–1271. [CrossRef]
- Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix
metalloproteinase 7 levels identifies poor prognosis advanced
colorectal cancer patients. Int J Cancer 2007;121:1066–1071. [CrossRef]
- Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix
metalloproteinase-2 and tissue inhibitor of metalloproteinase-1
correlate with disease stage and survival in colorectal cancer patients.
Dis Colon Rectum 2005;48:700–710.
- Giaginis C, Nikiteas N, Margeli A, et al. Serum tissue inhibitor of
metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal
cancer patients: associations with clinicopathological variables and
patient survival. Int J Biol Markers 2009;24:245–252.
- Holten-Andersen MN, Fenger C, Nielsen HJ, et al. Plasma TIMP-1 in
patients with colorectal adenomas: a prospective study. Eur J Cancer
2004;40:2159–2164. [CrossRef]
- Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High
preoperative plasma tissue inhibitor of metalloproteinase-1 levels
are associated with short survival of patients with colorectal cancer.
Clin Cancer Res 2000;6:4292–4299.
- Kawasaki T, Nosho K, Ohnishi M, et al. Cyclooxygenase-2
overexpression is common in serrated and non-serrated colorectal
adenoma, but uncommon in hyperplastic polyp and sessile serrated
polyp/adenoma. BMC Cancer 2008;8:33. [CrossRef]
- Wasilewicz MP, Kolodziej B, Bojulko T, Kaczmarczyk M, SulzycBielicka V, Bielicki D. Expression of cyclooxygenase-2 in colonic
polyps. Pol Arch Med Wewn 2010;120:313–320.
- Han YD, Hong YK, Kang JG, Choi YJ, Park Ch. Relation of the expression
of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to
angiogenesis and prognosis. J Korean Soc Coloproctol 2010;26:339–
346. [CrossRef]
- Wang WS, Lin JK, Chiou TJ, et al. Preoperative carcinoembryonic
antigen level as an independent prognostic factor in colorectal
cancer: Taiwan experience. Jpn J Clin Oncol 2000;30:12–16.
- Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence
after surgery for colorectal cancer. Colorectal Dis 2007;9:527–531.
[CrossRef]
- Stubbs RS, Nadkarni DM, Monsey HA. Faecal carcinoembryonic
antigen in colorectal cancer patients. Gut 1986;27:901–905.
- Sugano K, Ohkura H, Hirohashi S, et al. Detection of increased fecal
carcinoembryonic antigen and its characterization as a membranebound form in colorectal carcinoma and other gastrointestinal
disorders. Jpn J Cancer Res 1989;80:1156–1160.
- Kim Y, Lee S, Park S, et al. Gastrointestinal tract cancer screening using
fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003;33:32–38.
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from
colorectal cancer by screening for fecal occult blood. Minnesota
Colon Cancer Control Study. N Engl J Med 1993;328:1365–1371.
[CrossRef]
- Ransohoff DF, Lang CA. Screening for colorectal cancer with the
fecal occult blood test: a background paper. American College of
Physicians. Ann Intern Med 1997;126:811–822.
- Takai T, Kanaoka S, Yoshida K, et al. Fecal cyclooxygenase 2 plus
matrix metalloproteinase 7 mRNA assays as a marker for colorectal
cancer screening. Cancer Epidemiol Biomarkers Prev 2009;18:1888–
1893. [CrossRef]
- Karl J, Wild N, Tacke M, et al. Improved diagnosis of colorectal cancer
using a combination of fecal occult blood and novel fecal protein
markers. Clin Gastroenterol Hepatol 2008;6:1122–1128. [CrossRef]
- Hamaya Y, Yoshida K, Takai T, et al. Factors that contribute to faecal
cyclooxygenase-2 mRNA expression in subjects with colorectal
cancer. Br J Cancer 2010;102:916–921. [CrossRef]
- Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The
diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue
inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in
the sera of colorectal adenoma and cancer patients. Int J Colorectal
Dis 2010;25:1177–1184. [CrossRef]